Success Story: From NIW to EB-1B — Dual Approvals for an Indian Biomedical Science Expert under Premium Processing
Client’s Testimonial:
"Thank you so much for your support throughout the process.”
On October 31st, 2024, and April 27th, 2026, we received another EB-2 NIW (National Interest Waiver) and EB-1B (Outstanding Professors and Researchers) Approvals for an Assistant Professor in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Assistant Professor
Country of Origin: India
State of Residence at the Time of Filing: Oklahoma
Approval Notice Date: October 31st, 2024 & April 27th, 2026 (NIW & EB-1B)
Processing Time: 7 days (NIW, Premium Processing Requested) and 14 days (EB-1B, Premium Processing Requested)
Case Summary:
It is with great pleasure that we announce the approval of both an NIW and an EB-1B petition for a highly accomplished assistant professor in biomedical science, whose research spans mechanisms of chronic inflammatory disease, extracellular vesicle biology, neural-immune signaling, and intracellular trafficking.
Having first placed their trust in our firm for the NIW filing, this researcher returned to our team to pursue the more demanding EB-1B classification, which was subsequently approved. Notably, the NIW petition was approved in just 7 days, and the EB-1B petition followed with an equally impressive 14 days. Both petitions were filed with premium processing and approved without RFE, a testament to the strength and consistency of the cases our expert team built across every stage of this journey.
Accomplishments and Expertise
This researcher has established a strong reputation as a leading expert in biomedical science, with a particular focus on elucidating the molecular mechanisms underlying chronic inflammation and developing novel therapeutic and diagnostic approaches for respiratory and inflammatory diseases. This work carries direct implications for healthcare innovation, drug development, and the treatment of conditions affecting millions of patients across the United States.
In support of the petitions, our team highlighted several objective achievements, including:
- 15 peer-reviewed journal articles (3 of them first-authored), 2 peer-reviewed conference articles, and 10 first-authored conference abstracts
- 3,831 citations
- At least 18 peer reviews for top journals
- Research funding from the National Institute of General Medical Sciences (NIGMS) and the National Institutes of Health (NIH)
Letters of Recommendation
To further support the petitions, our firm obtained four letters of recommendation. One expert noted:
"It is clear that [Client] stands at the top of the field, given achievements in areas such as elucidating neural-immune signaling in chronic inflammation and identifying molecular targets that sustain inflammatory disease. Ensuring the continuation of [Client]’s work is thus deeply important to both biomedical science research and to the nation."
Dual Approval and Outlook
Our firm is honored to have supported this individual across two successful immigration milestones and extends its warmest congratulations. We look forward to seeing the continued contributions this researcher will make to advancing the understanding of chronic inflammation, improving patient outcomes, and driving biomedical innovation in the United States.